Latest Breaking News On - Worst itch numeric scale - Page 1 : comparemela.com

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0 05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0 05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoAmanda sheldonDerek coleLatha vairavanDrug administrationAmerican academy of dermatologyAmerican academy of dermatology annual meetingExchange commissionHead of corporate communicationsArcutis biotherapeutics incRoflumilast creamAtopic dermatitisChildren agesAmerican academyDermatology annual

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0 05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children.

San diegoUnited statesAmanda sheldonDerek coleLatha vairavanDrug administrationExchange commissionInvestor relations advisory solutionsHead of corporate communicationsAmerican academy of dermatologyArcutis biotherapeutics incEczema areaSeverity indexWorst itch numeric scaleInvestigator global assessmentAtopic dermatitis

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement .

San diegoUnited statesAmanda sheldonLatha vairavanDerek coleDrug administrationExchange commissionHead of corporate communicationsArcutis biotherapeutics incAmerican academy of dermatologyEczema areaSeverity indexWorst itch numeric scaleInvestigator global assessmentAtopic dermatitisAmerican academy

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0 05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children.

United statesSan diegoLatha vairavanAmanda sheldonDerek coleExchange commissionArcutis biotherapeutics incAmerican academy of dermatologyDrug administrationGlobenewswire incHead of corporate communicationsInvestor relations advisory solutionsEczema areaSeverity indexWorst itch numeric scaleInvestigator global assessment

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0 05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

19.09.2023 - Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% . Seite 1

Arcutis biotherapeutics incInvestigator global assessmentEczema areaSeverity indexWorst itch numeric scaleInvestigator globalAtopic dermatitisBody surface areaPediatric dermatologyArcutis biotherapeutics chartRcutis biotherapeutics kursArcutis biotherapeutics aktie